| Market Cap | 1.01B | P/E | - | EPS this Y | -16.70% | Ern Qtrly Grth | - |
| Income | -190.16M | Forward P/E | -5.56 | EPS next Y | 15.50% | 50D Avg Chg | 12.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 84.00% |
| Dividend | N/A | Price/Book | 2.31 | EPS next 5Y | - | 52W High Chg | -3.00% |
| Recommedations | 2.30 | Quick Ratio | 12.29 | Shares Outstanding | 47.86M | 52W Low Chg | 304.00% |
| Insider Own | 5.13% | ROA | -21.95% | Shares Float | 33.11M | Beta | -0.95 |
| Inst Own | 91.07% | ROE | -38.27% | Shares Shorted/Prior | 1.27M/1.73M | Price | 20.01 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 1,472,404 | Target Price | 21.00 |
| Oper. Margin | - | Earnings Date | Feb 27 | Volume | Change | 0.00% |
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts. As of October 14, 2022, Forma Therapeutics Holdings, Inc. operates as a subsidiary of Novo Nordisk A/S.
| Credit Suisse | Neutral | Sep 2, 22 |
| HC Wainwright & Co. | Neutral | Sep 2, 22 |
| Oppenheimer | Perform | Sep 2, 22 |
| Jefferies | Hold | Sep 2, 22 |
| SVB Leerink | Outperform | May 27, 22 |
| SVB Leerink | Outperform | Nov 12, 21 |
| HC Wainwright & Co. | Buy | Aug 17, 21 |
| Craig-Hallum | Buy | Aug 2, 21 |
| SVB Leerink | Outperform | Jun 11, 21 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Kelly Patrick F. | SVP, Chief Medical O.. SVP, Chief Medical Officer | Apr 13 | Option | 5.05 | 15,000 | 75,750 | 104,884 | 04/14/22 |
| Lee Frank D. | President and CEO President and CEO | Feb 23 | Sell | 9.7775 | 17,981 | 175,809 | 79,769 | 02/25/22 |
| Kelly Patrick F. | SVP, Chief Medical O.. SVP, Chief Medical Officer | Feb 23 | Sell | 9.7775 | 5,245 | 51,283 | 64,884 | 02/25/22 |
| Shegog Todd | SVP, Chief Financial.. SVP, Chief Financial Officer | Feb 23 | Sell | 9.7775 | 5,687 | 55,605 | 22,813 | 02/25/22 |
| Potts Jeannette | See Remarks See Remarks | Feb 23 | Sell | 9.7775 | 4,672 | 45,680 | 22,358 | 02/25/22 |